EN
SINOVAC Made Major Announcements Today
On June 4, 2024, Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin met with Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC, in Beijing, China.
Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin (Right) meet with
SINOVAC Chairman, President, and CEO Weidong Yin (Left)
SINOVAC, whose COVID-19 vaccines are the first to enter the Brazilian market during the pandemic, is a leading biopharmaceutical enterprise in China. Today, the company made major announcements of investment in Brazil as follows:
Firstly, SINOVAC plans to invest $100 million in Brazil starting in 2024, mainly for cell therapy and localized production of vaccines and monoclonal antibodies. Currently, SINOVAC is engaged in intensive discussions with potential partners.
Secondly, SINOVAC and Fiocruz jointly announced their intention to cooperate in vaccine research and development. In this way, both sides jointly strengthen their roles as the official representatives of Brazil and China, respectively, in the BRICS vaccine R&D center, established in 2022. This center aims to enhance the production capacity of participating countries and make access to vaccines more equitable. The institutions already signed the confidentiality document, which is the first step in establishing a partnership to search for solutions that expand access to vaccines and quickly combat pandemics and health crises. During the WHA77 in Geneva, BRICS health ministries reaffirmed their commitment to this important initiative for global health.
Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin meet with
Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.